GBM Stem Cell Compound Screening for Personalized Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glioblastoma multiforme (GBM) are largely ineffective due to the recurrence of the disease, with existing therapies failing to target and eliminate cancer stem cells, leading to inevitable tumor recurrence and poor patient prognosis.
Innovation Solution
A method involving the culturing of GBM stem cells, followed by exposure to a panel of compounds to identify combinations that cause significant cell death, allowing for the characterization of suitable treatments based on the compounds' ability to induce more than a threshold level of cell death and their potential to cross the blood-brain barrier, thereby identifying effective combinations for personalized chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat GBM, then initial tumor control may be achieved, but the disease recurs due to failure to target cancer stem cells
Solution Approach 1:
The patent performs preliminary identification of GBM stem cell susceptibility to various compounds before actual treatment. By culturing patient-derived GBM stem cells and screening them against compound panels in advance, the method determines which compounds will be effective for that specific patient, enabling personalized treatment selection before clinical intervention occurs.
Solution Approach 2:
The patent changes the parameter of treatment approach from standardized conventional therapy to personalized compound selection based on stem cell sensitivity profiling. By measuring specific responses of patient-derived stem cells to multiple compounds and identifying combinations that achieve threshold levels of cell death, the treatment parameters are customized to each patient's unique stem cell characteristics.
2Adaptability or versatility
If a panel of compounds is screened against GBM stem cells to identify effective combinations, then personalized treatment can be determined, but the process requires extensive culturing and testing time
Solution Approach 1:
The patent applies partial action by screening a selected panel of compounds rather than testing all possible treatments. The method identifies effective treatments by finding compounds that achieve a threshold level of stem cell death (e.g., 50% or greater), focusing on sufficient effectiveness rather than exhaustive testing of all potential compounds and combinations.
Solution Approach 2:
The patent segments the treatment selection process into distinct phases: (1) culturing patient-derived GBM stem cells, (2) screening against individual compounds in a panel, (3) identifying compounds that cause threshold-level cell death, and (4) selecting effective combinations. This segmentation allows systematic progression through the personalized treatment identification process.
3Measurement precision
If GBM stem cells are cultured from patient tissue to perform sensitivity testing, then accurate personalized treatment identification is possible, but the culturing process adds complexity to the overall workflow
Solution Approach 1:
The patent applies self-service by using the patient's own GBM stem cells (autologous cells) for the sensitivity testing. The stem cells are cultured from the patient's tumor tissue and then used to determine which treatments will work for that specific patient, eliminating the need for donor cells or complex animal models while maintaining high measurement precision.
Data Source
AI summary
A method of characterizing a glioblastoma multiforme (GBM) stem cell (GSC), comprising culturing the GSC to provide a culture, contacting a first set of aliquots of the culture with individual compounds selected from a panel of compounds, identifying two or more of the selected compounds that cause more than a threshold level of cell death in the first set of aliquots, and characterizing the GSC as suitable for treatment with one or more combinations comprising the two or more identified compounds. A panel of chemical compounds, the compounds selected by a method comprising surgically resecting the tumor, culturing a GSC derived from GBM tissue derived from a GBM tumor, contacting aliquots thereof with individual compounds selected from a panel of compounds, and identifying two or more of the selected compounds that cause more than a threshold level of cell death in the aliquots, thereby identifying the compounds.